Cagrilintide: Side Effects

Safety Profile Overview#

The safety profile of cagrilintide is characterized by clinical trial data from the phase 2 studies (Enebo et al., 2021; Frias et al., 2023) and emerging data from the phase 3 REDEFINE program. The adverse event profile is consistent with the known pharmacology of amylin receptor agonists and, in the case of CagriSema, the combined pharmacology of amylin and GLP-1 receptor agonism.

The most common adverse events are gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation. These effects are most prominent during the dose-titration phase and typically decrease in frequency and severity with continued treatment at the maintenance dose. The gastrointestinal adverse events are related to the pharmacological effects of both amylin receptor activation (which slows gastric emptying) and, in CagriSema, GLP-1 receptor activation (which has similar gastrointestinal effects).

Gastrointestinal Side Effects#

Nausea#

Nausea is the most frequently reported adverse event with cagrilintide, occurring in approximately 20 to 30% of participants receiving the 2.4 mg and 4.5 mg doses in the phase 2 monotherapy study. The incidence is higher with the CagriSema combination, where both components contribute to gastrointestinal effects. The majority of nausea episodes are mild to moderate in severity and occur predominantly during the dose-titration phase.

The mechanism of cagrilintide-induced nausea involves activation of amylin receptors in the area postrema, a brainstem region involved in the control of nausea and emesis. The area postrema is located outside the blood-brain barrier and is directly exposed to circulating peptide hormones. The gradual adaptation of these receptor systems during dose titration explains the typical reduction in nausea frequency over time.

Management strategies include adherence to the gradual dose-titration schedule, eating smaller and more frequent meals, avoiding high-fat or heavy meals that may exacerbate nausea, and temporary dose reduction if nausea is severe or persistent.

Vomiting and Diarrhea#

Vomiting and diarrhea are reported less frequently than nausea but follow a similar temporal pattern, with the highest incidence during dose titration. Vomiting occurred in approximately 5 to 10% of participants in the higher dose groups of the phase 2 study. Diarrhea was reported in approximately 10 to 15% of participants, typically mild in severity.

These adverse events are related to the effects of amylin and GLP-1 receptor activation on gastrointestinal motility. Both amylin and GLP-1 slow gastric emptying, which can contribute to a sensation of fullness, nausea, and, in some cases, vomiting. The effects on intestinal motility can produce either diarrhea or constipation depending on the individual response.

Gastroparesis Considerations#

The slowing of gastric emptying by cagrilintide (and more so by CagriSema) raises theoretical concerns about gastroparesis in susceptible individuals. Patients with pre-existing gastroparesis or severe gastrointestinal motility disorders may experience worsening of symptoms. Clinical trials generally excluded patients with clinically significant gastroparesis.

The delayed gastric emptying also has implications for the absorption of concomitant oral medications, particularly those with narrow therapeutic indices that depend on predictable absorption kinetics. This is discussed further in the Drug Interactions section.

Injection Site Reactions#

Injection site reactions including pain, redness, and induration are reported in clinical trials, though they are generally mild and do not require treatment discontinuation. The incidence of injection site reactions is comparable to other subcutaneously administered peptide therapies. Site rotation between the abdomen, thigh, and upper arm is recommended to minimize local reactions.

Metabolic Effects#

Blood Glucose#

Cagrilintide has glucose-lowering effects through multiple mechanisms including suppression of postprandial glucagon secretion, slowing of gastric emptying (which reduces postprandial glucose excursions), and weight loss. In clinical trials, the risk of hypoglycemia with cagrilintide monotherapy was low, as the glucose-lowering mechanism does not involve direct insulin stimulation.

However, when used in combination with insulin or sulfonylureas (particularly in the diabetic population), the additive glucose-lowering effect increases the risk of hypoglycemia. Dose reduction of insulin or sulfonylureas may be necessary when initiating cagrilintide in patients receiving these medications.

Heart Rate#

Like GLP-1 receptor agonists, amylin analogs may produce a small increase in resting heart rate (typically 2 to 4 beats per minute). The clinical significance of this effect is uncertain but should be considered in patients with pre-existing tachyarrhythmias.

Comparison with CagriSema Safety Profile#

The safety profile of CagriSema (cagrilintide plus semaglutide) reflects the combined adverse event profiles of both components. Gastrointestinal adverse events are more frequent with the combination than with either component alone, as both amylin and GLP-1 receptor activation contribute to nausea and delayed gastric emptying.

However, the combination does not appear to produce novel adverse events beyond those expected from the individual pharmacological profiles. The phase 2 data suggest that the additional gastrointestinal burden of the combination is manageable with appropriate dose titration and is offset by the substantially greater weight loss efficacy.

Thyroid Safety (CagriSema-Specific)#

The semaglutide component of CagriSema carries a boxed warning (for approved GLP-1 receptor agonist products) regarding the risk of thyroid C-cell tumors. In rodent studies, GLP-1 receptor agonists have been associated with thyroid C-cell hyperplasia and medullary thyroid carcinoma. This risk has not been confirmed in humans but remains a regulatory concern. Cagrilintide itself does not appear to carry this specific risk, but the CagriSema combination inherits the warning from its GLP-1 component.

Contraindications#

The contraindications for cagrilintide are based on the known pharmacology and the safety exclusion criteria used in clinical trials. For CagriSema, additional contraindications from the semaglutide component apply. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 is a contraindication for CagriSema. History of pancreatitis is a precaution for both components. Pregnancy and breastfeeding are contraindicated due to the absence of reproductive toxicology data in humans.

Drug Interactions#

The primary drug interactions for cagrilintide are related to its effects on gastric emptying. The slowing of gastric emptying can delay the absorption of orally administered medications, which may be clinically significant for drugs with narrow therapeutic indices or time-dependent absorption requirements. Oral contraceptives may have reduced efficacy due to altered absorption; barrier contraception is recommended during the titration phase and for 4 weeks after dose changes.

The intentional combination with semaglutide in CagriSema produces additive gastrointestinal effects. When used with insulin or sulfonylureas, dose reduction of the glucose-lowering medications should be considered to reduce hypoglycemia risk.

Related Reading#

• Cagrilintide overview and research guide
• Cagrilintide dosing protocols
• Cagrilintide risks and legal status